[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-disease":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,492,0,25,[9,47,72,96,119,140,168,195,223,240,261,279,299,332,358,380,410,437,465,489,522,544,569,589,617],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100633001","phase-2-a-phase-2b-clinical-trial-of-yn001-in-adults-with-coronary-atherosclerosis-100633001",false,"NCT07521007","A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis","A Randomized, Multicenter, Double-Blind, Parallel, Placebo-controlled Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Adults With Coronary Atherosclerosis","PURIFY-TIMI 81","Inclusion Criteria:\n\n1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.\n2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).\n3. Participants must satisfy either of the following criteria:\n\n1\\) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening\u002Fbaseline, as evidenced by:\n\n1. A history of Type 2 diabetes requiring treatment with medication,\n2. Aged \\> 55 years (women) or \\> 50 years (men),\n3. 2 or more of the following atherosclerosis risk factors:\n\n   * Current cigarette smoker\n   * Hypertension\n   * Estimated glomerular filtration rate (eGFR) 45 to 60 ml\u002Fmin\u002F1.73m2\n\n     4\\. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.\n\n     5\\. Female participants must be non-pregnant and non-lactating\n\n     6\\. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.\n\nExclusion Criteria:\n\n1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.\n2. Previously received YN001.\n3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period\n4. Contraindication for CCTA\n5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.\n6. Acute MI that occurred within 4 weeks prior to randomization.\n7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.\n8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.\n9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.\n10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.\n11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was \\\u003C40%.\n12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.\n13. History of myopathy or myositis, or susceptibility to myopathy\u002Frhabdomyolysis (e.g., family history of hereditary myopathy, etc.).\n14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.\n15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal\u002Frectal bleeding within 6 months prior to randomization.\n16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.\n17. Presenting with history of malignancy (except in participants who have been disease-free \\>5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).\n18. Presence of any type of autoimmune disease.\n19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.\n20. Life expectancy is less than 1 year.\n21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.\n22. Triglycerides ≥ 400 mg\u002FdL (4.5 mmol\u002FL) at final screening.\n23. LDL-C \\> 100 mg\u002FdL (2.6 mmol\u002FL) at final screening.\n24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), \\> 3 times upper limit of normal (ULN), or total bilirubin \\> 2 times ULN at final screening.\n25. Presence of renal dysfunction, defined by eGFR \\\u003C 45 ml\u002Fmin\u002F1.73m2.\n26. Untreated or inadequately treated hypothyroidism.\n27. Poorly controlled Type 2 diabetes mellitus.\n28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).\n29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.","ALL","18 Years","80 Years",{"count":22,"type":23},456,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.",[29,30],"Atherosclerosis","Coronary Artery Disease",[32,33],"Plaque regression","Plaque stabilization","RECRUITING","2026-08-20",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":38},"2026-07-31",{"date":42,"type":23},"2029-03-31",{"name":44,"class":45},"Beijing Inno Medicine Co., Ltd.","INDUSTRY",39,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100522551","spectroscopic-assessment-of-intramyocardial-oxygen-saturation-during-open-heart-surgery-100522551","NCT06084091","Spectroscopic Assessment of Intramyocardial Oxygen Saturation During Open-Heart Surgery","ECS","Inclusion Criteria:\n\n* Any 18 to 90-year-old patient scheduled for an open-heart operation\n* The ability to understand the study's objective and the risks involved.\n* Informed consent obtained, including the agreement to authorization to use the protected personal patient records according to privacy legislation.\n\nExclusion Criteria:\n\n* Inability to obtain an informed consent form\n* Patients included as vulnerable population according to Finnish Medical Research Act, including retarded, pregnant women, nursing mothers, prisoners, or forensic patients.","90 Years",{"count":56,"type":23},40,"OBSERVATIONAL","The goal of this observational study is to test in the safety and performance of intraoperative myocardial spectroscopic measurement in open-heart surgery patients\n\nThe main questions it aims to answer are:\n\n* The Devices can record myocardial spectrometric data for analysis, and\n* How these measures correlate with the occurring events, procedures, and clinical parameters during the operation.\n* Number of participants with device-related adverse events as assessed by CTCAE v4.0",[30,60],"Heart Valve Diseases",[62,63],"monitoring, intraoperative","Heart Surgery",{"date":37,"type":38},{"date":66,"type":38},"2023-10-06",{"date":68,"type":23},"2026-12-31",{"name":70,"class":45},"Spectrocor",1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":24,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":71},"100510211","routine-angiography-follow-up-after-percutaneous-coronary-intervention-in-high-risk-patients-100510211","NCT05923489","Routine Angiography Follow-Up After Percutaneous Coronary Intervention in High-Risk Patients","Routine Angiography Follow-Up After Percutaneous Coronary Intervention in High-Risk Patients (The REVISE Trial)","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Successful PCI with at least two of the following high-risk factors:\n\nA. Left main lesion; B. Bifurcation lesion (true bifurcation); C. Ostial lesion of main vessels (left anterior descending, left circumflex artery, right coronary artery); D. Chronic total occlusion; E. Multivessel revascularization (≥ 2 vessels); F. In-stent restenosis; G. Diffuse long lesion (lesion length ≥ 30 mm or stent length ≥ 38 mm); H. Severe calcified lesion (Significant severe calcification on angiography); I. Bypass graft lesion; J. Diabetes mellitus; K. Chronic kidney disease (defined as an estimated glomerular filtration rate of \\\u003C30 ml per minute per 1.73 m2 of body-surface area or the receipt of dialysis); L. Myocardial infarction;\n\n\\- He\u002Fshe or his\u002Fher legally authorized representative provides written informed\n\nExclusion Criteria:\n\n* Revascularization with bare metal stents and\u002For balloon angioplasty with non-drug-coated balloons.\n* Pregnant and\u002For lactating women.\n* Life expectancy of less than 2 years.\n* Repeat interventional therapy is planned.\n* Subject was unable to provide written informed consent.",{"count":80,"type":23},2618,[82],"NA","Comparison of clinical outcomes between routine angiography follow-up and routine clinical follow-up after percutaneous coronary intervention in high-risk patients.",[30],[86],"percutaneous coronary intervention","2026-08-19",{"date":37,"type":38},{"date":90,"type":38},"2023-10-26",{"date":92,"type":23},"2029-10-15",{"name":94,"class":95},"Second Affiliated Hospital, Zhejiang University, School of Medicine","OTHER",{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":18,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":24,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":71},"100652632","effect-of-high-intensity-interval-training-versus-home-based-rehabilitation-program-on-patients-underwent-coronary-artery-bypass-graft-surgery-100652632","NCT07775742","Effect of High-Intensity Interval Training Versus Home-Based Rehabilitation Program On Patients Underwent Coronary Artery Bypass Graft Surgery","Effect of High-Intensity Interval Training Versus Home-Based Rehabilitation Program on Peak Metabolic Equivalents On Patients Underwent Coronary Artery Bypass Graft Surgery","Inclusion Criteria:\n\n1. Participants will be eligible if they are clinically stable as defined by the American College of Cardiology\u002FAmerican Heart Association.\n2. Only Participants will be stratified as low to moderate risk as identified by the American College of Sport Medicine\u002F\n3. Mean age ± standard deviation, 55 ± 3 years.\n4. All patients underwent coronary artery bypass graft surgery, rested at home for at least one month, and then returned to the center for a cardiac rehabilitation program\n\nExclusion Criteria:\n\n1. Patients will be excluded from this study if they had an ejection fraction of less than 40% at rest (high risk as defined by American Association of Cardiovascular and Pulmonary Rehabilitation Stratification).\n2. Mental health disorders (such an anxiety or depression).\n3. Any vision or hearing defects or any neurological, respiratory, or musculoskeletal conditions that have an impact on ambulation.\n4. Irreversible heart failure.\n5. Myocardial Infarction (MI) over the past month.\n6. Persistent ventricular arrhythmias or unstable angina.\n7. Any exercise restrictions.","55 Years","58 Years",{"count":106,"type":23},84,[82],"1. To assess the effect of high-intensity interval training on peak metabolic equivalents in patients with coronary heart disease after the coronary artery bypass grafting surgery.\n2. To assess the effect of a home-based cardiac rehabilitation program on peak metabolic equivalents in patients with coronary heart disease after coronary artery bypass grafting surgery.\n3. To compare functional outcomes between the different treatment approaches.",[30,110],"Coronary Graft Stenosis","2026-08-18",{"date":35,"type":38},{"date":114,"type":38},"2026-07-01",{"date":116,"type":23},"2027-02-01",{"name":118,"class":95},"Kafrelsheikh University",{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":125,"enrollmentInfo":126,"targetDuration":128,"studyType":57,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100652348","identification-for-high-risk-of-coronary-heart-disease-based-on-quantitative-analysis-of-fundus-vessels-and-metabolic-molecules-100652348","NCT07773064","Identification for High Risk of Coronary Heart Disease Based on Quantitative Analysis of Fundus Vessels and Metabolic Molecules","Inclusion Criteria:\n\n* Older than 18 years\n* Symptoms suggestive of myocardial ischemia or the presence of multiple cardiovascular disease risk factors\n* Underwent coronary angiography during hospitalization\n* Underwent blood sample collection during hospitalization\n* Underwent bilateral color fundus photography during hospitalization\n* Availability of complete clinical data\n\nExclusion Criteria:\n\n* History of heart transplantation or other solid-organ transplantation\n* Severe heart failure, defined as New York Heart Association (NYHA) functional class IV or left ventricular ejection fraction (LVEF) ≤20%\n* History of severe congenital heart disease, valvular heart disease, myocardial disease, pericardial disease, or aortic dissection\n* Pregnancy, breastfeeding, or plans to become pregnant during the study period\n* Progressive life-threatening disease\n* History of alcohol or drug abuse\n* Current treatment for a psychiatric disorder\n* Current receipt of radiotherapy or chemotherapy for a malignant tumor\n* Acute or chronic infectious disease\n* Severe hepatic insufficiency, renal insufficiency, thyroid disease and autoimmune disease\n* Life expectancy of less than 5 years\n* Ophthalmic diseases affecting the retinal vasculature or optic disc structure, including retinal artery occlusion, retinal vein occlusion, glaucoma, or congenital optic disc abnormalities\n* Color fundus photographs of insufficient quality because of severe ocular media opacity","100 Years",{"count":127,"type":23},3000,"1 Year","This ambidirectional observational cohort study builds upon and expands an existing coronary artery disease (CAD) cohort based on retinal fundus imaging (ChiCTR2200066429). A comprehensive baseline database will be established, including demographic characteristics, laboratory test results, coronary angiography findings, quantitative retinal vascular features, and multi-omics data.Artificial intelligence methods will be used to quantify retinal vascular characteristics and to develop and validate models for identifying and predicting CAD. In addition, targeted liquid chromatography-tandem mass spectrometry (LC-MS\u002FMS) assays will be developed to measure previously identified CAD-related biomarkers, including metabolites and lipids, in baseline biological samples. Clinical, retinal imaging, and multi-omics data will subsequently be integrated to develop a risk stratification model for identifying individuals at high risk of CAD. Participants will be followed for cardiovascular events to evaluate the predictive performance of the model. The findings may support the development of improved strategies for CAD detection, risk assessment, and clinical management. No treatment or clinical intervention is assigned by the study protocol, and all medical decisions are made as part of routine clinical care.",[30],{"date":35,"type":38},{"date":133,"type":38},"2024-05-14",{"date":135,"type":23},"2027-12-31",{"name":137,"class":138},"Beijing Hospital","OTHER_GOV",3,{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":148,"targetDuration":4,"studyType":24,"phases":150,"briefSummary":151,"conditions":152,"keywords":156,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100615756","pivotal-study-of-the-supira-system-in-patients-undergoing-high-risk-percutaneous-coronary-intervention-hrpci-100615756","NCT07296744","Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)","Pivotal Randomized Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)","SUPPORT II","Inclusion Criteria:\n\n* Hemodynamically stable and will undergo elective or urgent (not emergent) HRPCI, where hemodynamic support is deemed necessary, as determined by the institutional Heart Team\n* Informed consent granted by the subject or legally authorized representative\n\nExclusion Criteria:\n\n* Cardiogenic shock or acutely decompensated pre-existing chronic heart failure\n* Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit\n* Left ventricular thrombus\n* Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the investigational device or the comparator device\n* Ongoing renal replacement therapy with dialysis\n* Presence of decompensated liver disease; severe liver dysfunction\n* Infection of the proposed procedural access site or active infection\n* Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol\n* Any condition, coagulopathy, planned procedure or contraindication that requires discontinuation of antiplatelet and\u002For anticoagulant therapy within 90 days of the index procedure\n* Breastfeeding or pregnant or planning to become pregnant within 90 days of the HRPCI procedure\n* Currently participating in active follow-up phase of another clinical study of an investigational drug or device or planning to enroll in such a study within 90 days of the HRPCI procedure\n* Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and\u002For to comply with study procedures\n* Considered to be part of a vulnerable population per the investigator's assessment",{"count":149,"type":23},358,[82],"The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. Eligible patients will be randomized to undergo HRPCI with either the Supira System (investigational device) or the commercially available Impella systems (comparator device).",[30,153,154,155],"High Risk Percutaneous Coronary Intervention","Interventional Cardiology","Mechanical Circulatory Support",[157,158,155,159],"Percutaneous ventricular assist device","Supira System","US Pivotal",{"date":87,"type":38},{"date":162,"type":38},"2026-05-11",{"date":164,"type":23},"2027-11",{"name":166,"class":45},"Supira Medical",19,{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":24,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100302428","randomization-of-single-vs-multiple-arterial-grafts-100302428","NCT03217006","Randomization of Single vs Multiple Arterial Grafts","Randomized Comparison of the Clinical Outcome of Single Versus Multiple Arterial Grafts: the ROMA Trial","ROMA","Inclusion Criteria:\n\n* Primary isolated CABG patients with disease of the left main coronary artery and\u002For of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.\n\nExclusion Criteria:\n\n* Age \\> 70 years\n* Single graft\n* Emergency operation\n* Evolving myocardial infarction within 48 hours of surgery\n* Left ventricular ejection fraction of \\\u003C 35%\n* Any concomitant cardiac or non-cardiac procedure\n* Previous cardiac surgery\n* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduce life expectancy to less than 5 years.\n* Inability to use the saphenous vein or to use both radial and right internal thoracic arteries\n* Anticipated need for coronary thrombo-endarterectomy\n* Planned hybrid revascularization","70 Years",{"count":178,"type":23},4300,[82],"The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and\u002For repeat revascularization. The secondary hypothesis is that in patients undergoing primary isolated non-emergent CABG, the use of two or more arterial grafts compared to a single arterial graft is associated with improved survival.\n\nProspective event-driven unblinded randomized multicenter trial of at least 4,300 subjects enrolled in at least 25 international centers. Patients will be randomized to a single arterial graft (SAG) or multiple arterial grafts (MAG). Patients will be randomized in a 1:1 fashion between the two groups. Permuted block randomization with random blocks stratified by the center and the type of second arterial graft will be used to provide treatment distribution in equal proportion.",[30,182],"Heart Diseases",[184,185,186],"coronary artery bypass surgery","multiple arterial graft","radial artery graft",{"date":35,"type":38},{"date":189,"type":38},"2018-01-07",{"date":191,"type":23},"2030-12-31",{"name":193,"class":95},"Weill Medical College of Cornell University",59,{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":24,"phases":205,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":219,"leadSponsor":221,"locationsCount":71},"100652055","ccta-based-vs-cag-based-cabg-a-multicenter-pragmatic-non-inferiority-trial-100652055","NCT07769008","CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial","Coronary Computed Tomography Angiography-Based Versus Coronary Angiography-Based Coronary Artery Bypass Grafting: A Multicenter Pragmatic Non-Inferiority Randomized Controlled Trial","CtaCAB","Inclusion Criteria:\n\n* Referred to CABG treatment\n\nExclusion Criteria:\n\n* Under the age of 18 years\n* Unable to provide informed consent\n* Emergency CABG\n* Redo-CABG\n* Prior PCI with coronary stent implantation\n* Cardiogenic shock\n* Unable to undergo CAG or CCTA examination or deemed unsuitable by the investigator, such as:\n\nKnown allergy to iodinated contrast media; Active hyperthyroidism or uncontrolled thyroid disease; Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²; Atrial fibrillation with rapid ventricular response or severe arrhythmias not amenable to rate control;\n\n* Pregnancy, lactation, or childbearing potential without effective contraception in female participants\n* Concurrent participation in another interventional trial",{"count":204,"type":23},826,[82],"The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive approach (called coronary angiography, or CAG) for people with blocked heart arteries.\n\nThe main questions it aims to answer are:\n\nDo people who have surgery planned with the non-invasive heart scan have similar health outcomes at 1 year as those who have surgery planned with the standard invasive approach? How does the non-invasive approach compare in terms of heart attacks, strokes, unplanned repeat procedures, and longer hospital stays? Researchers will compare two groups of participants. One group will have their surgery planned using only the CCTA . The other group will have their surgery planned using only the CAG. Both groups will undergo the CABG per local protocol.\n\nParticipants will:\n\nBe randomly assigned (like flipping a coin) to one of the two planning approaches Undergo CABG as scheduled Return for follow-up visits at sugery days, 7 days, 1 month, 6 months, and 1 year after surgery Have a follow-up CCTA scan at 7 days and 1 year to check if the new bypass grafts are working well",[30,208,209,210],"Coronary Artery Bypass Grafting","Coronary Computed Tomography Angiography","Coronary Angiography (CAG)",[212,213,214,215],"Major Adverse Cardiovascular Events (MACE)","Coronary Artery Bypass Grafting (CABG)","Coronary Computed Tomography Angiography(CCTA)","Coronary Angiography(CAG)","2026-08-17",{"date":87,"type":38},{"date":216,"type":38},{"date":220,"type":23},"2029-08",{"name":222,"class":95},"Ruijin Hospital",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":71},"100526651","risk-factors-and-outcomes-in-coronary-chronic-total-occlusion-100526651","NCT06137521","Risk Factors and Outcomes in Coronary Chronic Total Occlusion","Risk Factors and Outcomes in Patients With Stable Coronary Artery Disease and Coronary Chronic Total Occlusion","Inclusion Criteria:\n\n* Age ≥18 years; Patients with angina or silent ischemia and documented ischemia; Patients with CTO ≥ 3months\n\nExclusion Criteria:\n\n* eGFR\\\u003C15mL\u002F(min·1.73m2); Chronic heart failure with NYHA grade ≥3; Had a history of coronary artery bypass grafting; Had received a percutaneous coronary intervention within the prior 3 months; Malignant tumor or immune system disorders; Pulmonary heart disease",{"count":127,"type":23},"This study aims to assess the risk factors and evaluate the long-term outcomes of patients with coronary chronic total occlusion (CTO) treated with percutaneous coronary intervention or medical treatment.",[233,30],"Chronic Total Occlusion",{"date":111,"type":38},{"date":236,"type":38},"2010-01-01",{"date":238,"type":23},"2027-03-01",{"name":222,"class":95},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":71},"100447019","progress-bifurcation-global-registry-100447019","NCT05100992","Progress Bifurcation Global Registry","Prospective Global Registry of Percutaneous Coronary Intervention in Bifurcation Lesions (PROGRESS-BIFURCATION)","Inclusion Criteria:\n\n* Over 18 years of age\n* undergoing bifurcation percutaneous coronary intervention",{"count":248,"type":23},4000,"Coronary bifurcation lesions are lesions (or blockages) that occur at or near the intersection of a major coronary artery and one of the arteries' side branches.\n\nNumerous techniques and devices have been developed to treat coronary bifurcations; however, these types of lesions remain some of the most challenging, both in terms of procedural success and outcome. This study is designed as an observational, multi-center registry that will collect information on treatment strategies and outcomes of consecutive patients undergoing percutaneous coronary interventions (PCI) in coronary bifurcations among various participating centers, in order to determine the frequency of bifurcation PCI, the procedural strategies utilized, and the procedural outcomes.",[30,251],"Coronary Bifurcation Lesions",[253,86],"bifurcation lesions",{"date":87,"type":38},{"date":256,"type":38},"2020-04-23",{"date":258,"type":23},"2030-01",{"name":260,"class":95},"Minneapolis Heart Institute Foundation",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":278,"locationsCount":71},"100447015","progress-complication-100447015","NCT05100940","Progress Complication","Prospective Global Registry of Complications of Percutaneous Coronary Interventions","* Over 18 years of age\n* undergoing coronary angiography or PCI\n* A complication occurred during or after the procedure",{"count":248,"type":23},"Coronary angiography and percutaneous coronary intervention (PCI) is often performed in patients with ischemic heart disease. The safety of PCI has improved with new devices and strategies, but complications still occur, especially during complex procedures. The objectives of this multi-center observational registry are to examine frequency of complications occuring during cardiac catheterization and PCI, examine procedural strategies utilized for complication management, and evaluate the clinical outcomes (both immediate and during follow-up.)",[30],[272,273],"complications","Percutaneous Coronary intervention",{"date":87,"type":38},{"date":276,"type":38},"2020-11-24",{"date":191,"type":23},{"name":260,"class":95},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":287,"targetDuration":128,"studyType":57,"phases":4,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":297,"locationsCount":298},"100213888","prospective-global-registry-for-the-study-of-chronic-total-occlusion-intervention-100213888","NCT02061436","Prospective Global Registry for the Study of Chronic Total Occlusion Intervention","Multicenter Registry of Chronic Total Occlusion Interventions","PROGRESS-CTO","Inclusion Criteria:\n\n* Patients undergoing CTO PCI at each of the participating centers.\n\nExclusion Criteria:\n\n* None",{"count":288,"type":23},2000,"Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to determine the frequency of CTO PCI performed at the participating sites and examine the procedural strategies utilized, and the procedural (both immediate and during follow-up) outcomes.",[30],[292],"chronic total occlusion, percutaneous coronary intervention",{"date":87,"type":38},{"date":295,"type":38},"2012-01",{"date":258,"type":23},{"name":260,"class":95},48,{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":327,"leadSponsor":329,"locationsCount":331},"100172884","product-surveillance-registry-100172884","NCT01524276","Product Surveillance Registry","Medtronic Product Surveillance Registry","PSR","Inclusion Criteria:\n\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n* Patient has or is intended to receive or be treated with an eligible Medtronic product\n* Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n* Patient who is, or will be, inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results",{"count":308,"type":23},100000,"The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.",[311,312,313,314,315,316,155,317,318,319,320,321,322,323,30,324],"Cardiac Rhythm Disorders","Urological Disorders","Neurological Disorders","Cardiovascular Disorders","Digestive Disorders","Intracranial Aneurysm","Respiratory Therapy","Aortic, Peripheral Vascular and Venous Disorders","Minimally Invasive Surgical Procedures","Diagnostic Techniques and Procedures","Surgical Procedures, Operative","Renal Insufficiency","Neurovascular","Ear, Nose and Throat Disorder",{"date":111,"type":38},{"date":295,"type":4},{"date":328,"type":23},"2040-01",{"name":330,"class":45},"Medtronic",400,{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":340,"targetDuration":341,"studyType":57,"phases":4,"briefSummary":342,"conditions":343,"keywords":347,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":71},"100652467","cold-region-exposure-and-cardiac-remodeling-after-pci-100652467","NCT07773870","Cold-Region Exposure and Cardiac Remodeling After PCI","Association of Cumulative Cold-Region Exposure With Left Ventricular Remodeling and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Multicenter Prospective Observational Cohort Study","COLD-PCI","Inclusion Criteria:\n\n* Age 18 to 75 years. Angiographically confirmed coronary artery disease treated with successful percutaneous coronary intervention, defined as residual stenosis \\\u003C30% with final TIMI grade 3 flow.\n\nClinically stable after PCI. Expected survival of at least 12 months. Able and willing to undergo baseline cardiovascular magnetic resonance imaging and baseline and 6-month transthoracic echocardiography.\n\nAble to provide residential, occupational, training\u002Fdeployment, and other relevant exposure histories for the 3 years preceding PCI.\n\nWritten informed consent provided.\n\nExclusion Criteria:\n\n* Severe valvular heart disease, cardiomyopathy, congenital heart disease, or other major structural heart disease.\n\nPrevious coronary artery bypass grafting or heart transplantation. End-stage heart failure or New York Heart Association class IV heart failure. Severe renal dysfunction, defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m².\n\nKnown contraindication to cardiovascular magnetic resonance imaging or gadolinium-based contrast agents.\n\nInability to complete transthoracic echocardiographic assessment. Inability to reliably recall or verify major residential or occupational exposure history during the 3 years preceding PCI.\n\nMore than five major changes in primary residence during the 3 years preceding PCI that preclude reliable estimation of cumulative cold-region exposure.",{"count":331,"type":23},"12 Months","This multicenter prospective observational cohort study aims to investigate the association between cumulative cold-region exposure and adverse left ventricular remodeling and cardiovascular outcomes in patients with coronary artery disease undergoing successful percutaneous coronary intervention (PCI).\n\nIndividual-level chronic cold exposure will be quantified primarily by cumulative months of residence, work, or other relevant exposure in cold regions during the 3 years preceding PCI. Additional exposure measures will include regional cold-wave days derived from meteorological records and winter outdoor occupational exposure.\n\nParticipants will undergo baseline cardiovascular magnetic resonance (CMR), echocardiography, electrocardiography, and clinical and laboratory assessment after PCI. Echocardiography will be repeated at 6 months to assess left ventricular remodeling. Cardiovascular events will be prospectively collected during follow-up.\n\nThe study will evaluate whether cumulative cold-region exposure is associated with distinct CMR phenotypes, adverse left ventricular remodeling, and major adverse cardiovascular events (MACE), and whether cold-exposure measures provide incremental prognostic information beyond conventional clinical, imaging, and electrocardiographic risk markers.",[30,344,345,346],"Percutaneous Coronary Intervention (PCI)","Left Ventricular Remodeling","Cold Exposure",[345,348,346,349],"Cardiac Magnetic Resonance Imaging","Acute Myocardial Infarction","2026-08-16",{"date":87,"type":38},{"date":353,"type":38},"2026-06-30",{"date":355,"type":23},"2028-12-30",{"name":357,"class":95},"Chinese PLA General Hospital",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":24,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":71},"100652175","hemostatc-pad-and-sandbag-100652175","NCT07771127","HEMOSTATİC PAD AND SANDBAG","Comparison of Factors Related to Bleeding, Pain, Comfort Level, and Sleep Quality in Patients Undergoing Femoral Coronary Angiography Using a Chitosan-Containing Hemostatic Pad Versus a Sandbag","Inclusion Criteria:\n\n* Patients aged 18 years and older scheduled for femoral coronary angiography (CAG) and\u002For percutaneous coronary intervention (PCI)\n* Patients undergoing a single femoral arterial access procedure\n* Patients with sheath size typically 5-Fr, 6-Fr, or 7-Fr\n* Patients who are conscious, alert, and able to communicate\n* Patients who voluntarily agreed to participate in the study\n\nExclusion Criteria:\n\n* Patients with known allergy to shellfish or chitosan Patients using antihistamines, psychotropic medications, or sleep medications Patients with systolic and\u002For diastolic blood pressure above 150\u002F100 mmHg Patients with known bleeding disorders (e.g., hemophilia) or active bleeding Patients with severe renal or hepatic failure Pregnant or breastfeeding patients Patients with a history of malignancy",{"count":366,"type":23},480,[82],"The aim of this study is to compare bleeding outcomes, pain, comfort levels, sleep quality, and associated factors among patients receiving a chitosan-based hemostatic pad versus a sandbag following femoral coronary angiography (CAG) and percutaneous coronary intervention (PCI).\n\nFemoral coronary angiography (CAG) and percutaneous coronary intervention (PCI) are widely performed procedures for the diagnosis and treatment of coronary artery disease (CAD), which remains the leading cause of mortality worldwide (Batmaz \\& Cengiz, 2023; Wardiyana et al., 2024). Hemostasis following CAG and PCI is critical for preventing life-threatening complications, ensuring procedural success, and facilitating recovery. Vascular complications at the femoral arterial puncture site are among the most common adverse events associated with these procedures (Chen et al., 2021). Inadequate hemostasis may result in serious complications such as pseudoaneurysm, arteriovenous fistula, and retroperitoneal hemorrhage, all of which may pose significant risks to patient safety (Sauer et al., 2016). Effective bleeding control is particularly important in patients receiving intensive anticoagulant therapy.\n\nFollowing manual compression, sandbag application is commonly used to maintain hemostasis at the femoral access site. Typically, a sandbag weighing between 2.3 and 5 kilograms is placed over the puncture site, requiring patients to remain in a supine position with restricted mobility for approximately four to six hours (Batmaz \\& Cengiz, 2023). Although prolonged bed rest and sandbag application contribute to hemostasis, they may also lead to adverse patient experiences, including pain, discomfort, urinary retention, restlessness, and impaired sleep quality (Batmaz \\& Cengiz, 2023).\n\nAdvances in medical technology have led to the development of hemostatic devices designed to rapidly control bleeding independently of the body's natural coagulation mechanisms. Among these, chitosan-based hemostatic pads, derived from crustacean shells, have attracted increasing attention. Due to their positive electrical charge, chitosan molecules attract negatively charged erythrocytes and platelets, facilitating the rapid formation of a mechanical barrier and clot within seconds (Arbel et al., 2010; Kılıç et al., 2024). Previous studies have demonstrated that chitosan-based pads may reduce manual compression time and vascular complications such as ecchymosis and hematoma (Ginanjar et al., 2018; Kılıç et al., 2024; Qian et al., 2024). Furthermore, they have been associated with improved patient comfort, earlier mobilization, and shorter hospital stays (Kılıç et al., 2024; Liu, 2025).\n\nThe responsibilities of nurses following CAG and PCI extend beyond bleeding control and include comprehensive monitoring of vital signs, early detection of complications, and the promotion of patient comfort and well-being (Batmaz \\& Cengiz, 2023; Rodrigues et al., 2024). While existing studies have primarily focused on the effectiveness of chitosan-based pads in reducing hematoma formation (Bektaş et al., 2017), evidence regarding their effects on broader patient-centered outcomes remains limited. Therefore, this study seeks to provide a comprehensive evaluation of chitosan-based hemostatic pads and conventional sandbag application with respect to bleeding outcomes, pain, patient comfort, and sleep quality.\n\nAccordingly, the present study aims to compare bleeding, pain, comfort levels, sleep quality, and related factors among patients undergoing femoral CAG and PCI who receive either a chitosan-based hemostatic pad or a sandbag for post-procedural hemostasis.\n\nThe sample size was calculated using a power analysis based on an effect size of 0.40, a significance level of 5% (α = 0.05), and a statistical power of 80% (1-β = 0.80). According to the analysis, a total of 480 participants will be recruited, including 240 patients in the chitosan-based hemostatic pad group and 240 patients in the sandbag group.",[30,370,371],"Coronary Angiography","Vascular Access Site Complications","2026-08-13",{"date":111,"type":38},{"date":375,"type":38},"2026-06-10",{"date":377,"type":23},"2026-12-30",{"name":379,"class":95},"Uludag University",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":18,"minAge":387,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":390,"briefSummary":391,"conditions":392,"keywords":395,"overallStatus":401,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":71},"100651715","sedentary-behavior-intervention-for-older-adults-with-coronary-heart-disease-and-frailty-100651715","NCT07762898","Sedentary Behavior Intervention for Older Adults With Coronary Heart Disease and Frailty","Development and Application of a Sedentary Behavior Intervention Program Based on the Integrated Theory of Health Behavior Change for Older Adults With Coronary Heart Disease and Frailty","Inclusion Criteria:\n\n* Age 60 years or older.\n* Diagnosis of stable coronary artery disease according to the Chinese Primary -Care Guideline for Stable Coronary Artery Disease (2020).\n* Canadian Cardiovascular Society (CCS) angina class I or II.\n* Fried Frailty Phenotype score of 1 or higher, including participants with pre-frailty (score 1-2) or frailty (score 3-5).\n* Total sedentary time of 6 hours or more per day.\n* The participant or the participant's primary caregiver is able to use the WeChat application.\n* Able and willing to provide informed consent and voluntarily participate in the study.\n\nExclusion Criteria:\n\n* Currently participating in another research study.\n* Presence of a malignant tumor.\n* Presence of a severe infectious disease.\n* Presence of a physical impairment that substantially limits limb mobility.\n* Presence of a language impairment that prevents effective communication or -completion of study assessments.\n* Presence of cognitive impairment that prevents understanding of study procedures or completion of study assessments.","60 Years",{"count":389,"type":23},64,[82],"This study aims to evaluate the feasibility and effectiveness of a sedentary behavior intervention based on the Integrated Theory of Health Behavior Change (ITHBC) in older adults with coronary heart disease and frailty. Participants will be randomly assigned to an intervention group or a control group. The intervention is designed around the three core components of ITHBC-knowledge and beliefs, self-regulation skills and abilities, and social facilitation-to help participants reduce sedentary behavior, improve physical activity, and enhance their ability to manage health-related behaviors. The study will include a 1-month intervention period followed by a 2-month follow-up period, with a total study duration of 3 months for each participant. Changes in sedentary behavior and other health-related outcomes will be assessed throughout the study period.",[30,393,394],"Sedentary Behavior","Prefrailty",[396,397,398,399,400],"Integrated Theory of Health Behavior Change","Older Adults","Behavior Change","Sedentary Time","Physical Activity","NOT_YET_RECRUITING","2026-08-12",{"date":372,"type":38},{"date":405,"type":23},"2026-09",{"date":407,"type":23},"2027-01",{"name":409,"class":95},"Gansu University of Chinese Medicine",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":417,"sex":18,"minAge":418,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":24,"phases":421,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":435,"locationsCount":71},"100560521","phase-4-hyperemic-myocardial-perfusion-by-adenosine-at-different-doses-100560521","NCT06578234","Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses","HYPER","Inclusion Criteria:\n\nPatients:\n\n1. The subject has given their written consent to participate in the trial.\n2. Are referred to Department of Clinical Physiology, Skåne University Hospital, for suspected or known CCS or heart failure\n3. Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \\>80 years old)\n4. Matches the inclusion criteria for no known heart failure (group b) or known heart failure (group c)\n5. No caffein intake \\\u003C24h prior to the examination\n\nHealthy volunteers:\n\n1. The subject has given their written consent to participate in the trial.\n2. Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \\>80 years old)\n3. No caffein intake \\\u003C24h prior to the examination\n\nExclusion Criteria:\n\nPatients:\n\n1. Acute referral (in-house patients)\n2. Clinically unstable\n3. Acute chest pain\n4. Severe or decompensated heart failure\n5. Non sinus rhythm (e.g. atrial fibrillation)\n6. Asthma or severe chronic obstructive pulmonary disease\n7. Known chronic renal failure (eGFR \\\u003C45mL\u002Fmin\u002F1.73m2)\n8. AV-block II or III\n9. Left Bundle Branch Block\n10. Systolic blood pressure \\\u003C90 mmHg or \\>230 mmHg at rest\n11. Increased intracranial pressure\n12. Known allergy or adverse reaction to adenosine or mannitol\n13. Known allergy or adverse reaction to gadolinium contrast agents\n14. Treatment with medication containing dipyradimol or teofyllamin\u002Fteofyllin\n15. Claustrophobia\n16. Devices contraindicated to CMR imaging (pacemaker, implants, intracranial clips etc)\n17. Pregnancy or breast feeding (screened by question only)\n18. Inability to give informed consent due to mental state, language difficulties etc\n\nHealthy volunteers:\n\n1. Any of the exclusion criteria for patients\n2. Blood pressure \\> 140\u002F90 measured according to clinical routine\n3. Known systemic disease\n4. Known cardiac disease\n5. Cardiovascular medication\n6. Medication that might influence cardiovascular health\n7. Smoking",true,"40 Years",{"count":420,"type":23},180,[422],"PHASE4","Adenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substantial number of patients, leading to false diagnostics. The aim of this trial is to investigate the hyperemic effect of the standard dose of adenosine (140 microgram\u002Fkg\u002Fmin) to the high dose of adenosine (210 microgram\u002Fkg\u002Fmin) to improve the diagnostic methods using adenosine as a stressor and ultimately improve treatment decisions and patient prognosis in CCS.",[425,30,426],"Chronic Coronary Syndrome","Ischemic Heart Disease",[428,429,430],"Myocardial perfusion","Cardiac Magnetic Resonance","Adenosine",{"date":372,"type":38},{"date":433,"type":38},"2024-10-23",{"date":68,"type":23},{"name":436,"class":95},"Region Skane",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":24,"phases":447,"briefSummary":448,"conditions":449,"keywords":452,"overallStatus":401,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":463,"locationsCount":71},"100651954","effect-of-eye-mask-use-on-sleep-quality-and-delirium-after-cabg-surgery-100651954","NCT07768020","Effect of Eye Mask Use on Sleep Quality and Delirium After CABG Surgery","The Effect of Eye Mask Use on Sleep Quality and Delirium Levels in Patients Following Coronary Artery Bypass Graft Surgery","EYE-CABG","Inclusion Criteria:\n\n* Aged 18 years or older\n* Scheduled to undergo elective coronary artery bypass graft surgery\n* Conscious, cooperative, and oriented\n* No diagnosed cognitive impairment that would prevent informed consent or completion of the study assessments\n* Able to communicate in Turkish\n* Baseline Nursing Delirium Screening Scale (Nu-DESC) score below 2\n* Able and willing to use an eye mask\n* Voluntarily agreed to participate and provided written informed consen\n\nExclusion Criteria:\n\n* Diagnosed sleep disorder\n* Regular use of sleep medication\n* Habitual use of an eye mask during sleep\n* Severe visual impairment or an ocular, facial, or skin condition preventing the safe use of an eye mask\n* Severe communication impairment preventing completion of the data collection instruments\n* Undergoing emergency coronary artery bypass graft surgery",{"count":446,"type":23},100,[82],"Coronary artery bypass graft (CABG) surgery is an effective treatment for coronary artery disease; however, sleep disturbances and delirium are common during the postoperative period and may adversely affect recovery. Environmental factors, particularly light exposure, can disrupt the sleep-wake cycle and contribute to poor sleep quality. Eye masks offer a simple, safe, and non-pharmacological method of reducing light exposure and supporting sleep. This study aims to determine the effect of eye mask use on sleep quality and delirium levels in patients following CABG surgery.",[30,450,451],"Sleep Quality","Postoperative Delirium (POD)",[208,453,450,454,455,456,457],"Eye Mask","Postoperative Delirium","Cardiac Surgery","Non-Pharmacological Intervention","Postoperative Nursing Care","2026-08-11",{"date":216,"type":38},{"date":461,"type":23},"2026-09-15",{"date":377,"type":23},{"name":464,"class":95},"Munzur University",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":472,"targetDuration":128,"studyType":57,"phases":4,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":401,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":71},"100651873","a-prospective-multicenter-real-world-registry-of-quantitative-flow-ratio-guided-coronary-revascularization-and-quality-evaluation-100651873","NCT07766434","A Prospective Multicenter Real-World Registry of Quantitative Flow Ratio-Guided Coronary REvascularization and QuAlity evaLuation","QFR-REAL","Inclusion Criteria:\n\n* Age ≥18 years\n* Coronary angiography showing visually estimated at least one main branch coronary stenosis ≥50% in patients with acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction \\>4 weeks after onset) or chronic coronary syndrome (including stable angina and asymptomatic myocardial ischemia) who undergo PCI or receive conservative treatment\n* Ability to understand the study design and provide written informed consent\n\nExclusion Criteria:\n\n* ST-segment elevation myocardial infarction within 4 weeks of onset\n* History of coronary artery bypass grafting (CABG) or planned CABG within 6 months\n* Inability to undergo coronary angiography\n* Non-cardiac cause with expected survival \\\u003C1 year\n* Other conditions that may interfere with follow-up (e.g., dementia, substance abuse including drug addiction and other drug dependencies)\n* Refusal to participate in the study",{"count":473,"type":23},10000,"This prospective, multicenter observational registry aims to establish a QFR-based quality control standard system for coronary revascularization in patients with coronary artery disease. The study will enroll over 10,000 patients with visually estimated at least one main branch coronary stenosis ≥50% from more than 50 centers across China (covering provincial, municipal, and county-level hospitals). Coronary angiographic images and intracoronary imaging (if available) will be collected and retrospectively analyzed by an independent core laboratory. The primary endpoint is QFR acquisition accessibility, defined as the mean of QFR usage proportion across centers.",[30],[477,478,479,480],"Quantitative Coronary Angiography","Quantitative Flow Ratio","Percutaneous Coronary Intervention","Myocardial Ischaemia",{"date":482,"type":38},"2026-08-14",{"date":484,"type":23},"2026-08",{"date":486,"type":23},"2029-07",{"name":488,"class":138},"China National Center for Cardiovascular Diseases",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":24,"phases":499,"briefSummary":500,"conditions":501,"keywords":505,"overallStatus":401,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":71},"100651536","phase-4-icosapent-ethyl-for-high-risk-coronary-plaques-assessed-by-18f-naf-petct-100651536","NCT07762755","Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET\u002FCT","A Randomized Controlled Trial Evaluating the Effect of Icosapent Ethyl on High-Risk Coronary Plaques Using 18F-Sodium Fluoride PET\u002FCT","IPE-NaF","Inclusion Criteria:\n\n* Male or female participants aged 18 to 75 years.\n* Ability to understand the study and provide written informed consent before enrollment.\n* Receiving a stable lipid-lowering regimen before enrollment, with the type and dose of statin therapy remaining unchanged for at least 4 weeks.\n* Fasting triglyceride level below 5.6 mmol\u002FL.\n* Presence of at least one of the following high-risk plaque features on coronary computed tomography angiography (CCTA):Pericoronary fat attenuation index greater than -70.1 Hounsfield units;\n* Low-attenuation plaque below 30 Hounsfield units;\n* Positive remodeling index greater than 1.1;\n* Spotty calcification;\n* or Napkin-ring sign, defined as a low-attenuation plaque core surrounded by a rim of higher attenuation.\n\nExclusion Criteria:\n\n* Current participation in another investigational drug, device, or procedure study, or receipt of an investigational drug or device within 4 weeks before enrollment.\n* Treatment with icosapent ethyl within 12 months before enrollment.\n* Known intolerance or hypersensitivity to icosapent ethyl or fish oil.\n* A previous diagnosis of homozygous familial hypercholesterolemia or hyperlipidemia requiring hemodialysis.\n* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, or stroke within 3 months before enrollment;\n* Planned cardiac surgery, percutaneous coronary intervention, or carotid artery stenting, or planned major noncardiac surgery during the study.\n* A known contraindication or limitation to PET\u002FCT, including exceeding scanner weight limits or having a device, carotid or aortic stent, or vascular graft that may cause imaging artifacts.\n* Autoimmune disease, vasculitis, or active inflammatory disease.\n* Serious infection within 1 month before enrollment or a current infection requiring intravenous antibiotic treatment.\n* Use within 6 weeks before enrollment or current use of medications that may significantly affect plaque inflammation, including oral, rectal, or injectable corticosteroids or immunosuppressive agents, such as cyclosporine, methotrexate, tacrolimus, azathioprine, antithymocyte globulin, sirolimus, anti-tumor necrosis factor agents such as infliximab, anti-interleukin-6 therapy such as tocilizumab, or anti-interleukin-1 therapy.\n* Use within 6 weeks before enrollment or current use of aspirin at a dose greater than 325 mg\u002Fday or nonsteroidal anti-inflammatory drugs at a dose greater than 1,000 mg\u002Fday.\n* Treatment within 12 months before enrollment with a cholesteryl ester transfer protein inhibitor, including anacetrapib, dalcetrapib, or evacetrapib, or with mipomersen or lomitapide.\n* Known clinically significant systemic disease, including hepatic, renal, hematologic, or malignant disease, or any other clinically significant comorbidity that may interfere with study participation or study assessments.\n* History of malignancy within the previous 5 years, except nonmelanoma skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, or stage I prostate cancer.\n* Inability or anticipated inability to complete all protocol-required visits or procedures, or any condition that may make the participant unreliable for study participation, including alcohol or other substance abuse within the previous year or a psychiatric disorder.\n* Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during study treatment or within 15 weeks after the last dose of study treatment.","75 Years",{"count":446,"type":23},[422],"This randomized controlled study will evaluate whether icosapent ethyl (IPE) can improve and stabilize high-risk coronary plaques in patients receiving stable low-density lipoprotein cholesterol (LDL-C)-lowering therapy. Potential participants will have coronary plaques identified by coronary computed tomography angiography (CCTA), with 30% to 70% narrowing in at least one major coronary artery and at least one high-risk plaque feature.\n\nAfter baseline imaging with fluorine-18 sodium fluoride positron emission tomography\u002Fcomputed tomography (18F-NaF PET\u002FCT), eligible participants will be randomly assigned in a 1:1 ratio to receive either IPE 2 g twice daily plus standard LDL-C-lowering therapy or standard LDL-C-lowering therapy alone for 12 months. At the end of treatment, participants will undergo repeat CCTA and 18F-NaF PET\u002FCT. Blood biomarkers and major adverse cardiovascular events will also be assessed during follow-up.",[30,502,503,504],"Hyperlipidaemia","Hypertriglyceridaemia","Coronary Atherosclerosis",[506,507,508,509,504,510,511,512,209,513,514,515],"Icosapent Ethyl","IPE","High-Risk Coronary Plaque","Coronary Plaque Stabilization","Intermediate Coronary Stenosis","18F-Sodium Fluoride PET\u002FCT","18F-NaF PET\u002FCT","CCTA","Coronary Microcalcification","Pericoronary Fat Attenuation Index",{"date":372,"type":38},{"date":518,"type":23},"2026-08-01",{"date":520,"type":23},"2029-12-31",{"name":488,"class":138},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":530,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":24,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":543},"100471413","phase-4-tailored-versus-coventional-antiplatelet-strategy-intended-after-optimized-drug-eluting-stent-100471413","NCT05418556","Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug","OPTIMIZE-APT","Inclusion Criteria:\n\n1. Men or women ≥19 years\n2. Typical chest pain or objective evidence of myocardial ischemia suitable for PCI\n3. Significant de novo coronary artery lesions suitable for DES implantation\n4. Patients who underwent optimized stent implantation either by IVUS or OCT\n\n   * Using IVUS\n\n     * MSA \\>5.5 mm2, or MSA \\>90% of the MLA at the distal reference segment\n     * Plaque burden \\\u003C50% with 5 mm of both stent edge\n     * No edge dissection, thrombus or plaque protrusion\u002Fstent area \\\u003C10%\n   * Using OCT\n\n     * MSA \\>4.5 mm2, or MSA \\>90% of the MLA at the distal reference segment\n     * No significant malapposition\n     * No significant edge dissection, thrombus or plaque protrusion\u002Fstent area \\\u003C10%\n5. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site\n\nExclusion Criteria:\n\n1. Angiographic exclusion criteria: any of the followings 1. Bypass graft lesions 2. Lesions in which impaired delivery of imaging catheters is expected:\n\n   * Extreme angulation (≥90°) proximal to or within the target lesion.\n   * Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.\n   * Heavy calcification proximal to or within the target lesion.\n2. In-stent restenosis\n3. Hypersensitivity or contraindication to device material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated.\n4. Persistent thrombocytopenia (platelet count \\\u003C80,000\u002Fμl)\n5. Any history of hemorrhagic stroke or intracranial hemorrhage \u002F TIA or ischemic stroke within the past 6 months\n6. A known intolerance or hypersensitivity to a study drug (aspirin, clopidogrel or ticagrelor) or heparin\n7. Patients requiring long-term oral anticoagulants or cilostazol\n8. Any surgery requiring general anesthesia or discontinuation of aspirin and\u002For an ADP antagonist is planned within 12 months after the procedure.\n9. A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.\n10. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.\n11. History of liver cirrhosis (Child-Pugh B or C) or biliary tract obstruction\n12. Life expectancy \\\u003C 1 years for any non-cardiac or cardiac causes\n13. Cardiogenic shock at the index admission\n14. Patient's pregnant or breast-feeding\n15. Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease, gastrointestinal pathology with a high risk for bleeding, malignancies with a high risk for bleeding)\n16. Unwillingness or inability to comply with the procedures described in this protocol.","19 Years",{"count":532,"type":23},3944,[422],"Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT)\n\nHypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and noninferior for ischemic composite adverse events in patients who received intravascular imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS\u002FOCT could act as an essential criterion for decision making for tailored antithrombotic strategy)",[30],{"date":372,"type":38},{"date":538,"type":38},"2022-10-21",{"date":540,"type":23},"2032-12-31",{"name":542,"class":95},"Asan Medical Center",33,{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":552,"targetDuration":128,"studyType":57,"phases":4,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":71},"100651696","impact-of-procedural-factors-on-drug-coated-balloon-outcomes-in-coronary-artery-disease-100651696","NCT07764094","Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease","Impact of Drug-Coated Balloon Procedural Factors on Angiographic and Clinical Outcomes of Percutaneous Coronary Intervention for De Novo Lesions: A Multicenter, Prospective, Observational Registry","DT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Stable coronary artery disease or unstable angina\n3. De novo coronary lesion (reference vessel diameter 2.25-4.0 mm; lesion length ≤40 mm)\n4. Planned DCB strategy for PCI\n5. Written informed consent\n\nExclusion Criteria:\n\n1. Acute myocardial infarction within 72 hours\n2. Severe heart failure (NYHA class IV)\n3. Severe hepatic or renal insufficiency\n4. Allergy to drug-coated balloon components or antiplatelet agents, or intolerance to dual antiplatelet therapy\n5. Life expectancy \\\u003C12 months\n6. Pregnancy or breastfeeding\n7. Concurrent participation in another clinical trial\n8. In-stent restenosis\n9. Unsuccessful recanalization of main vessel or side branch chronic total occlusion\n10. Hemodynamic instability",{"count":553,"type":23},500,"This registry aimed to investigate drug-coated balloon procedural factors (particularly delivery time and inflation duration) to evaluate the impact on angiographic and clinical outcomes in patients undergoing percutaneous coronary intervention for de novo coronary lesions.",[556,557,30],"PCI","Drug-coated Balloon",[559,560],"Percutaneous coronary intervention","Drug coated balloon","2026-08-09",{"date":372,"type":38},{"date":564,"type":23},"2026-09-01",{"date":566,"type":23},"2028-06-30",{"name":568,"class":95},"Nanjing First Hospital, Nanjing Medical University",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":576,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":578,"conditions":579,"keywords":582,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":586,"leadSponsor":588,"locationsCount":71},"100651545","progression-management-and-clinical-outcomes-of-coronary-artery-aneurysms-100651545","NCT07764081","Progression, Management, and Clinical Outcomes of Coronary Artery Aneurysms","Progression, Management Strategies, and Risk Factors of Coronary Artery Aneurysms: A Multicenter, Retrospective Cohort Study","Inclusion Criteria:\n\n1. Angiographically confirmed coronary artery aneurysm, defined as coronary dilation ≥1.5 times the adjacent normal reference vessel diameter.\n2. Age 18-80 years.\n\nExclusion Criteria:\n\n1. Suboptimal image quality\n2. Incomplete clinical data, including medical history, laboratory parameters, or follow-up records.",{"count":577,"type":23},1000,"This study aimed to characterize the progression and risk fators of coronary artery aneurysms, and copmpare the outcomes across different management strategies",[30,580,581],"Aneurysms","Coronary Intervention",[583],"Coronary Artery Aneurysms",{"date":372,"type":38},{"date":40,"type":23},{"date":587,"type":23},"2028-08-30",{"name":568,"class":95},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":597,"targetDuration":599,"studyType":57,"phases":4,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":401,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":616},"100651515","turkish-chronic-total-occlusion-percutaneous-coronary-intervention-registry-100651515","NCT07761624","Turkish Chronic Total Occlusion Percutaneous Coronary Intervention Registry","Turkish Chronic Total Occlusion Percutaneous Coronary Intervention Prospective Multicenter Observational Registry: TURK-CTO Registry","TURK_CTO","Inclusion Criteria:\n\n* Age ≥18 years\n* Presence of at least one coronary chronic total occlusion (CTO), defined as a coronary artery lesion with TIMI grade 0 antegrade flow and an estimated duration of occlusion of ≥3 months\n* Undergoing an attempted PCI of the CTO at a participating center during the study period\n* Provision of informed consent when required by the applicable ethics committee and local regulations\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Coronary lesion not meeting the predefined criteria for CTO\n* No attempted CTO PCI during the procedure\n* Inability or refusal to provide informed consent when informed consent is required\n* Withdrawal of consent from participation in the registry",{"count":598,"type":23},70000,"3 Years","The TURK CTO Registry is a prospective, multicenter, observational registry designed to evaluate the contemporary management and outcomes of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in Türkiye.\n\nThe registry will include consecutive adult patients undergoing CTO PCI at participating centers. Detailed data on patient characteristics, cardiovascular risk factors, lesion and procedural characteristics, CTO crossing strategies, guidewires and devices, procedural techniques, radiation exposure, contrast use, procedural success, and in-hospital complications will be collected using a standardized electronic data collection system.\n\nThe primary objective of the registry is to characterize contemporary CTO PCI practice in Türkiye and to evaluate procedural success and safety. Secondary objectives include identifying clinical, angiographic, and procedural factors associated with technical and procedural success, complications, resource utilization, and patient outcomes.\n\nThe registry is expected to provide real-world, multicenter data on CTO PCI practice and to help identify factors associated with successful and safe CTO revascularization in Türkiye. No treatment or procedural strategy will be assigned by the study protocol; all clinical and procedural decisions will be made by the treating physicians according to routine clinical practice.",[602,30],"Chronic Total Occlusion (CTO)",[604,605,86,606,607,608],"chronic total occlusion","coronary artery disease","antegrade approach","retrograde approach","Turk-Cto Registry",{"date":402,"type":38},{"date":611,"type":23},"2026-07-24",{"date":613,"type":23},"2036-07-24",{"name":615,"class":95},"Ahmet Seyfeddin Gürbüz",6,{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":625,"targetDuration":626,"studyType":57,"phases":4,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":71},"100641396","assessment-of-ct-ffr-in-patients-with-ccs-a-prospective-multicenter-cohort-study-100641396","NCT07659119","Assessment of CT-FFR in Patients With CCS: A Prospective Multicenter Cohort Study","Assessment of Coronary Computed Tomography-Derived Fractional Flow Reserve in Patients With Chronic Coronary Syndrome: A Prospective Multicenter Cohort Study","ACCURATE-PRO","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of chronic coronary syndrome (CCS).\n* Completed coronary computed tomography angiography (CCTA) examination and successfully obtained CT-derived fractional flow reserve (CT-FFR) results.\n* The subject or their legal representative voluntarily participates in this study and has signed the written informed consent form.\n\nExclusion Criteria:\n\n* Acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or acute episodes of unstable angina.\n* Unable to obtain valid CT-FFR results, or the image quality is insufficient to support analysis.\n* Pregnant patients or those who intend to become pregnant during the study period.\n* Non-cardiac comorbidities indicating a life expectancy of less than one year.\n* Failure to sign the informed consent form.\n* Inability to complete the follow-up or explicit refusal to participate in the follow-up.\n* Patients with cognitive impairment or psychiatric disorders confirmed by clinical diagnosis or investigator assessment.\n* Patients who are illiterate or semi-literate, or who, due to any visual impairment or reading\u002Fwriting disability, are unable to independently read the subject information sheet without assistance and are unable to personally provide written informed consent.\n* Any other conditions deemed unsuitable for participation in this study by the investigators",{"count":127,"type":23},"5 Years","The ACCURATE-PRO study is an investigator-initiated, prospective, multicenter, observational, real-world cohort study. The core objective in managing chronic coronary syndrome (CCS) is to identify clinically significant myocardial ischemia to guide treatment decisions and improve long-term prognosis. While coronary computed tomography angiography (CCTA) is a crucial non-invasive anatomical imaging tool, it has limitations in determining the functional significance of coronary stenosis. Computed tomography-derived fractional flow reserve (CT-FFR) provides this functional assessment non-invasively based on CCTA images. However, there is a lack of systematic, prospective, multicenter evidence regarding its clinical value in risk stratification, treatment decision support, and prognostic evaluation for a continuous, real-world spectrum of CCS patients in China.\n\nThis study aims to evaluate the relationship between abnormal CT-FFR results and the risk of 1-year major adverse clinical events in CCS patients undergoing CCTA and CT-FFR. The study hypothesizes that abnormal CT-FFR is associated with a higher risk of 12-month major adverse clinical events, and that CT-FFR results are significantly correlated with subsequent treatment strategies, providing important value in risk stratification and mid-to-long-term prognosis.\n\nThe trial plans to consecutively enroll approximately 3,000 patients across multiple clinical centers in China. Eligible participants must be 18 years or older, have a clinical diagnosis of CCS, and have successfully obtained CT-FFR results following a CCTA examination. Patients will be excluded if they have acute coronary syndrome (such as STEMI, NSTEMI, or acute unstable angina), unanalyzable CT-FFR results\u002Fimage quality, or non-cardiac conditions limiting their life expectancy to less than one year.\n\nSince this is an observational study, it will not alter routine clinical care pathways or assign interventions. The primary exposure factor analyzed will be the lowest CT-FFR result per patient, comparing an abnormal CT-FFR group (≤ 0.80) to a normal CT-FFR group (\\> 0.80).\n\nParticipants will be followed up via telephone, outpatient visits, or hospitalization at 6, 12, 24, and 60 months after enrollment. The primary endpoint is a composite of all-cause death, myocardial infarction (MI), or ischemia-driven revascularization within 1 year after enrollment. Key secondary endpoints include the occurrence of the primary endpoint at 24 and 60 months, target vessel failure (a composite of cardiac death, target vessel MI, or target vessel revascularization), stroke, health economics analysis, and the association between CT plaque characteristics and clinical outcomes.",[30],{"date":402,"type":38},{"date":631,"type":38},"2024-09-23",{"date":633,"type":23},"2034-05-31",{"name":94,"class":95}]